Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...

In another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular ...

Investing.com-- TD Cowen downgraded its rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) and slashed its price target ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research ...

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...

I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...

Currently, the analyst consensus on Roku is a Moderate Buy with an average price target of $86.83, which is a 5.67% upside from current levels. In a report released yesterday, Citizens JMP also ...

CSL Behring’s Andembry is now approved as a subcutaneous, self-injection for hereditary angioedema (HAE) patients ages 12 and older and will be available by the end of June 2025.

The bank's head of blockchain solutions Philippe Meyer told the DigiAssets conference in London that it started advising on ...